An Open-labeled, International, Multicenter, Dose Escalating, Phase I/II Trial of HuMax-CD20, a Fully Human Monoclonal Anti-CD20 Antibody, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

GlaxoSmithKline2 个研究点分布在 1 个国家开始时间: 2004年10月1日最近更新: 2015年4月21日

适应症

试验速览

The purpose of this trial is to determine the safety and efficacy of HuMax-CD20 as a treatment for Chronic Lymphocytic Leukemia.

•Previous treatment with rituximab or alemtuzumab within 6 months prior to enrollment in study.
•Previous stem cell transplantation.
•Received any of the following treatments within 4 weeks prior to entering this trial: A) Anti-cancer therapy, B) Glucocorticoids unless less than 10 mg per day, C) Radiotherapy.
•HIV positivity.
•Hepatitis B or hepatitis C.
•Other cancerous diseases, except certain skin cancers and cervix cancer.
•Certain serious medical conditions, including kidney or liver disease, some psychiatric illnesses, and stomach, heart, hormonal, nerve or blood diseases.
•Participation in another trial with a different new drug 4 weeks prior to enrollment in study.
•Current participation in any other clinical study.
•Pregnant or breast-feeding women.
•Women of childbearing age who are unable or unwilling to use adequate contraception.

发起方

申办方类型

Industry

Loading locations...